You are here:Home-Chemical Inhibitors & Agonists-Ras-Raf-MAPK-ERK Pathway-Ras-RSC-1255
RSC-1255

Chemical Structure : RSC-1255

CAS No.: 2171015-78-2

RSC-1255 (KRAS inhibitor 249C, RSC1255)

Catalog No.: PC-49554Not For Human Use, Lab Use Only.

RSC-1255 (KRAS inhibitor 249C, V-ATPase inhibitor) is a Ras-mutant selective cytotoxic agent with nanomolar potency against a spectrum of Ras-mutant cancer cells (A549 (KRASG12S), IC50=73 nM), binds to V-ATPase (Kd=23 nM) and inhibits its activity.

Packing Price Stock Quantity
25 mg Get quote
50 mg Get quote
100 mg Get quote
250 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

    Biological Activity

    RSC-1255 (KRAS inhibitor 249C, V-ATPase inhibitor) is a Ras-mutant selective cytotoxic agent with nanomolar potency against a spectrum of Ras-mutant cancer cells (A549 (KRASG12S), IC50=73 nM), binds to V-ATPase (Kd=23 nM) and inhibits its activity.
    249C (RSC-1255) shows inhibition of viability in both Ras- and Raf-mutant cells with IC50 of 73 nM, 60 nM and 22 nM for A549 (KRASG12S), LOX IMVI (BRAFV600E), and MelJuso (HRASG13D and NRASQ61L), respectively.
    249C (RSC-1255) blocks lysosomal acidification and autophagy progression. blocked ATP hydrolysis of intact mammalian V-ATPase purified from pig kidneys (but not yeast).
    249C (RSC-1255) differentially inhibits fibroblasts bearing mutations in KRAS and BRAF via inhibition of lysosomal pH, V-ATPase activity, and macropinocytosis.
    249C (RSC-1255) preferentially kills mouse embryonic fibroblasts bearing specific KRAS mutations with IC50 values: KRAS WT (1.25 µM); G13D (0.07 µM); G12V (0.15 µM); G12S (0.23 µM); G12D (0.3 µM); Q61L (0.31 µM); G12C (0.44 µM); Q61R (0.55 µM); and for BRAFV600E (0.11 µM).
    249C (RSC-1255) inhibits macropinocytosis in a KRAS-mutant-dependent manner in MEFs expressing KRAS/BRAF mutants (KRASG13D, KRASG12V, and BRAFV600E), but less so in MEFs expressing KRAS WT.
    249C (RSC-1255) treatment (10 mg/kg, twice a day, i.p.) inhibits in vivo growth of mutant KRAS (KRASG12S) in mouse xenograft models and shows pharmacodynamic safety.

    Physicochemical Properties

    M.Wt 564.966
    Formula C27H25ClF4N4O3
    Appearance Solid
    CAS No.
    Storage
    Solide Powder
    -20°C 12 Months; 4°C 6 Months
    In Solvent
    -80°C 6 Months; -20°C 6 Months
    Shipping
    Solubility

    10 mM in DMSO

    Chemical Name/SMILES

    4-(5-chlorofuran-2-yl)-1,3-bis(2,4-difluorophenyl)-5-methyl-N-((4-methylmorpholin-2-yl)methyl)-4,5-dihydro-1H-pyrazole-5-carboxamide

    References

    1. Bhairavi Tolani, et al. Nat Biotechnol. 2022 Dec;40(12):1834-1844.

    Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

    Contact Us sales@probechem.com

    Bulk Inquiry

    * Indicates a Required FieldYour information is safe with us.

    • *Product name:
    • *Applicant name:
    • *Email address:
    • *Organization name:
    • *Requested quantity:
    • *Country:
    • *Additional Information:

    Get Quote

    * Indicates a Required FieldYour information is safe with us.

    • *Product name:
    • *Applicant name:
    • *Email address:
    • *Organization name:
    • *Requested quantity:
    • *Country:
    • Additional Information: